Key result
Vaccination with an adenovirus-vectored FMDV vaccine protected cattle from viremia and clinical disease, despite subclinical infection persisting in the nasopharyngeal mucosa.
Why the study?
Does a recombinant adenovirus-vectored FMDV vaccine prevent viremia and clinical FMD in cattle following intra-nasopharyngeal virus exposure?
Population
16 approximately six-month-old Holstein steers
Comparison
Recombinant adenovirus-vectored FMDV serotype A… vs Non-vaccinated steers
Design
Preclinical
Follow-up
Up to 96 hours post-infection
Authors
Loading...
May guide FMDV vaccine development in livestock; leaves open whether nasopharyngeal persistence drives transmission.
Does a recombinant adenovirus-vectored FMDV vaccine prevent viremia and clinical FMD in cattle following intra-nasopharyngeal virus exposure?
Vaccination with an adenovirus-vectored FMDV vaccine protects cattle from viremia and clinical disease but does not prevent subclinical infection in the nasopharynx.
Stenfeldt et al. (2015) studied Foot-and-mouth disease virus (FMDV) infection (n=16). Recombinant adenovirus-vectored FMDV vaccine (Ad5-FMDV) vs. Non-vaccinated was evaluated on Viremia and clinical FMD. Vaccination with an adenovirus-vectored FMDV vaccine protected cattle from viremia and clinical disease, despite subclinical infection persisting in the nasopharyngeal mucosa.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: